– Interview with Selena Bartlett, Ph.D., Director, Preclinical Development Group, Gallo Research Center, University of California-San Francisco

Previous articleFDA Maintains Clinical Hold on HBV Vaccine from Dynavax and Merck & Co.
Next articleMaxygen to Delay Development of Lead Program and Cut 30% of Jobs